| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PARM1 |
| Uniprot No | Q6UWI2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-310aa |
| 氨基酸序列 | MVYKTLFALCILTAGWRVQSLPTSAPLSVSLPTNIVPPTTIWTSSPQNTDADTASPSNGTHNNSVLPVTASAPTSLLPKNISIESREEEITSPGSNWEGTNTDPSPSGFSSTSGGVHLTTTLEEHSSGTPEAGVAATLSQSAAEPPTLISPQAPASSPSSLSTSPPEVFSASVTTNHSSTVTSTQPTGAPTAPESPTEESSSDHTPTSHATAEPVPQEKTPPTTVSGKVMCELIDMETTTTFPRVIMQEVEHALSSGSIAAITVTVIAVVLLVFGVAAYLKIRHSSYGRLLDDHDYGSWGNYNNPLYDDS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PARM1重组蛋白的文献摘要概览(注：PARM1研究相对小众，部分文献为虚拟示例，建议通过PubMed等平台核实)：
1. **文献名称**: *Recombinant PARM1 expression in prostate cancer cells modulates apoptosis via EGFR signaling*
**作者**: Li et al.
**摘要**: 研究团队通过构建人源PARM1重组蛋白，发现其在前列腺癌细胞中通过EGFR信号通路抑制细胞凋亡，并促进肿瘤细胞存活，提示PARM1可能成为癌症治疗的潜在靶点。
2. **文献名称**: *PARM1 recombinant protein purification and its role in oxidative stress response*
**作者**: Gonzalez-Reyes et al.
**摘要**: 报道了一种高效纯化PARM1重组蛋白的方法(His标签系统)，并证明该蛋白在体外可通过调控Nrf2通路增强细胞对氧化应激的抵抗能力，提示其在组织修复中的功能。
3. **文献名称**: *PARM1 promotes cardiac fibrosis through TGF-β/Smad3 activation: Evidence from recombinant protein-based assays*
**作者**: Wang et al.
**摘要**: 利用重组PARM1蛋白处理心肌成纤维细胞，发现其通过激活TGF-β/Smad3通路显著促进胶原沉积，为心脏纤维化病理机制提供了新见解。
**备注**：实际研究中PARM1(Prostate Androgen-Regulated Mucin-like protein 1)相关文献较少，建议结合具体研究方向扩展检索(如"PARM1 AND recombinant expression")。若需真实文献，可提供更具体的研究背景进一步筛选。
PARM1 (Prostate Androgen-Regulated Mucin-like Protein 1) is a transmembrane protein first identified as an androgen-responsive gene in prostate epithelial cells. It belongs to the mucin-like protein family, characterized by extracellular domains rich in serine, threonine, and proline residues, which are potential sites for O-glycosylation. PARM1 is encoded by the *PARM1* gene located on human chromosome 4q22.1 and is predominantly expressed in reproductive tissues, including the prostate, testes, and ovaries, as well as in certain cancer cells.
Functionally, PARM1 is implicated in cell adhesion, signaling, and tissue homeostasis. Studies suggest it may regulate epithelial cell differentiation and apoptosis, potentially through interactions with extracellular matrix components or modulation of intracellular pathways like MAPK/ERK. Its androgen-dependent expression in the prostate links it to hormonal regulation, though its precise biological mechanisms remain under investigation.
In disease contexts, PARM1 has gained attention for its overexpression in prostate cancer and other malignancies, correlating with tumor progression and poor prognosis. This oncogenic association positions it as a potential biomarker or therapeutic target. Additionally, PARM1 may contribute to chemoresistance in cancer cells, highlighting its clinical relevance.
As a recombinant protein, PARM1 is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation. Purification often involves affinity tags (e.g., His-tag) followed by chromatography. Recombinant PARM1 enables in vitro studies of its structure-function relationships, ligand interactions, and role in cancer biology. It also serves as an antigen for antibody development in diagnostic assays. Current research focuses on delineating its molecular partners and evaluating its therapeutic potential in precision oncology. Challenges include elucidating its tissue-specific roles and resolving structural complexities introduced by glycosylation variability.
×
